Advertisement

Neurological Sciences

, Volume 35, Issue 5, pp 753–758 | Cite as

Substantia nigra in Parkinson’s disease: a multimodal MRI comparison between early and advanced stages of the disease

  • Domenico Aquino
  • Valeria Contarino
  • Alberto Albanese
  • Ludovico Minati
  • Laura Farina
  • Marina Grisoli
  • Antonio Elia
  • Maria Grazia Bruzzone
  • Luisa Chiapparini
Original Article

Abstract

This study focused on the substantia nigra (SN) in Parkinson’s disease (PD). We measured its area and volume, mean diffusivity (MD), fractional anisotropy (FA) and iron concentration in early and late PD and correlated the values with clinical scores. Twenty-two early PD (EPD), 20 late PD (LPD) and 20 healthy subjects (age 64.7 ± 4.9, 60.5 ± 6.1, and 61 ± 7.2 years, respectively) underwent 1.5 T MR imaging with double-TI-IR T1-weighted, T2*-weighted and diffusion tensor imaging scans. Relative SN area, MD, FA and R2* were measured in ROIs traced on SN. Correlation with Unified Parkinson Disease Rating Scale (UPDRS) scores was assessed. In LPD, the SN area was significantly reduced with respect to EPD (p = 0.04) and control subjects (p < 0.001). In EPD, the SN area was also significantly smaller than in controls (p = 0.006). Similarly, the SN volume significantly differed between LPD and controls (p = 0.001) and between EPD and LPD (p = 0.049), while no significant differences were found between controls and EPD. Both SN area (r = 0.47, p = 0.004) and volume (r = 0.46, p = 0.005) correlated with UPDRS scores. At 1.5 T, SN morphological measurements were sensitive to early PD changes and able to track the disease progression, while MD and FA measures and relaxometry did not provide significant results.

Keywords

Parkinson disease UPDRS Substantia nigra Inversion recovery Diffusion tensor imaging Relaxometry 

Notes

Acknowledgments

This work was funded by the Italian Ministry of Health, RF 110 (ex art 56), year 2010.

Conflict of interest

There were no real or perceived conflicts of interest.

References

  1. 1.
    Halliday G, Lees A, Stern M (2011) Milestones in Parkinson’s disease—clinical and pathologic features. Mov Disord 26:1015–1021PubMedCrossRefGoogle Scholar
  2. 2.
    Seppi K, Poewe W (2010) Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 20:29–55PubMedCrossRefGoogle Scholar
  3. 3.
    Dickson DW, Braak H, Duda JE et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157PubMedCrossRefGoogle Scholar
  4. 4.
    Chahine LM, Stern MB (2011) Diagnostic markers for Parkinson’s disease. Curr Opin Neurol 24:309–317PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson JM, Levey AI, Rajput A et al (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson’s disease. Neurology 47:718–726PubMedCrossRefGoogle Scholar
  6. 6.
    Innis RB, Seibyl JP, Scanley BE et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90:11965–11969PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Leenders KL, Oertel WH (2001) Parkinson’s disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. Neural Plast 8:99–110PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P (2004) PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences. Neuroimage 23:1–16PubMedCrossRefGoogle Scholar
  9. 9.
    Hutchinson M, Raff U (2008) Detection of Parkinson’s disease by MRI: spin–lattice distribution imaging. Mov Disord 23:1991–1997PubMedCrossRefGoogle Scholar
  10. 10.
    Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M (2007) Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 28:309–313PubMedGoogle Scholar
  11. 11.
    Vaillancourt DE, Spraker MB, Prodoehl J et al (2009) High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 72:1378–1384PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 118(6):939–957PubMedCrossRefGoogle Scholar
  13. 13.
    Carroll CB, Zeissler ML, Chadborn N et al (2011) Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson’s disease. Neurochem Int 59:73–80PubMedCrossRefGoogle Scholar
  14. 14.
    Martin WR, Wieler M, Gee M (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70:1411–1417PubMedCrossRefGoogle Scholar
  15. 15.
    Péran P, Cherubini A, Assogna F et al (2010) Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 133:3423–3433PubMedCrossRefGoogle Scholar
  16. 16.
    Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G (2009) Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 48:29–36PubMedCrossRefGoogle Scholar
  17. 17.
    Hutchinson M, Raff U (1999) Parkinson’s disease: a novel MRI method for determining structural changes in the substantia nigra. J Neurol Neurosurg Psychiatry 69:815–818CrossRefGoogle Scholar
  18. 18.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442PubMedCrossRefGoogle Scholar
  20. 20.
    Brazzelli M, Capitani E, Della Sala S, Spinnler H, Zuffi M (1994) A neuropsychological instrument adding to the description of patients with suspected cortical dementia: the Milan overall dementia assessment. J Neurol Neurosurg Psychiatry 57:1510–1517PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A (2009) Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson’s disease: long-term observation. Mov Disord 24:557–563PubMedCrossRefGoogle Scholar
  22. 22.
    Fahn S, Elton RL (1987) Members of the UPDRS Development Committee. Unified Parkinsons disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinsons disease, 2nd edn. Macmillan Healthcare Information, Florham Park, pp 153–163Google Scholar
  23. 23.
    Raff U, Hutchinson M, Rojas GM, Huete I (2006) Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation. Acad Radiol 13:721–727PubMedCrossRefGoogle Scholar
  24. 24.
    Basser PJ, Pierpaoli C (1996) Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 111:209–219PubMedCrossRefGoogle Scholar
  25. 25.
    Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3:41–51PubMedCrossRefGoogle Scholar
  26. 26.
    Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N (2009) Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology 252:165–172PubMedCrossRefGoogle Scholar
  27. 27.
    Gattellaro G, Minati L, Grisoli M, Mariani C, Carella F, Bruzzone MG (2009) White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 30:1222–1226PubMedCrossRefGoogle Scholar
  28. 28.
    Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X (2011) Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson’s disease. Mov Disord 26:1627–1632PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Meijer FJA, Bloem RB, Mahlknecht P, Seppi K, Goraj B (2013) Update on diffusion MRI in Parkinson’s disease and atypical parkinsonism. J Neurol Sci 332(2013):21–29PubMedCrossRefGoogle Scholar
  30. 30.
    Chan LL, Rumpel H, Yap K, Lee E, Loo HV, Ho GL et al (2007) Case control study of diffusion tensor imaging in Parkinson’s disease. J Neurol Neurosurg Psychiatry 78(12):1383–1386PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Domenico Aquino
    • 1
  • Valeria Contarino
    • 1
  • Alberto Albanese
    • 2
  • Ludovico Minati
    • 3
  • Laura Farina
    • 1
  • Marina Grisoli
    • 1
  • Antonio Elia
    • 2
  • Maria Grazia Bruzzone
    • 1
  • Luisa Chiapparini
    • 1
  1. 1.Neuroradiology DepartmentIRCCS Foundation Neurological Institute Carlo BestaMilanItaly
  2. 2.1st Neurology UnitIRCCS Foundation Neurological Institute Carlo BestaMilanItaly
  3. 3.Scientific DepartmentIRCCS Foundation Neurological Institute Carlo BestaMilanItaly

Personalised recommendations